Novavax Inc (NVAX)

R&D Expenses

$70.69M

Quarterly · Period ending: · USD

NVAX logo

NVAX R&D Expenses

Latest reported$70.69M
NVAX Quarterly R&D Expenses ($800.00K → $70.69M)
High-resolution chart · PNG

NVAX r&d expenses history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Novavax Inc R&D Expenses — Quarterly (USD)
Period endingR&D Expenses (USD)
70,693,000
95,472,000
73,976,000
98,274,000
77,633,000
88,937,000
104,380,000
87,164,000
106,946,000
92,679,000
164,697,000
106,229,000
219,475,000
247,101,000
257,850,000
304,297,000
289,648,000
383,483,000
962,957,000
408,195,000
570,685,000
592,671,000
401,199,000
294,087,000
34,846,000
16,895,000
29,341,000
18,611,000
30,417,000
35,473,000
43,415,000
41,326,000
44,542,000
44,514,000
49,657,000
41,862,000
39,263,000
37,654,000
51,100,000
52,983,000
64,904,000
68,952,000
75,903,000
27,917,000
25,042,000
25,888,000
30,495,000
19,219,000
15,202,000
14,518,000
16,319,000
13,948,000
10,785,000
9,432,000
9,412,000
6,395,000
5,176,000
5,077,000
648,000
6,239,000
5,584,000
5,414,000
4,806,000
7,870,000
6,327,000
9,029,000
10,961,000
5,256,000
5,297,000
4,266,000
5,865,000
8,655,000
5,380,000
4,434,000
4,113,000
5,634,000
4,193,000
3,659,000
3,193,000
2,903,000
3,401,000
2,032,000
1,316,000
1,161,000
1,377,000
1,222,000
1,541,000
1,552,000
1,229,000
3,047,000
2,345,000
2,554,000
2,792,000
2,365,000
1,653,000
3,702,000
3,205,000
2,942,000
2,589,000
1,757,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.